| Literature DB >> 15206060 |
Erin Quirk1, Howard McLeod, William Powderly.
Abstract
Although the ever-expanding armamentarium of antiretroviral drugs has significantly decreased the morbidity and mortality due to human immunodeficiency virus infection, patients and clinicians are increasingly faced with the problems of inadequate or toxic response to therapy that may be genetically mediated. Significant evidence now exists that interindividual differences, such as efficacy of therapy, hypersensitivity reactions, and metabolic complications as a result of antiretroviral therapy, are in part genetically determined. This article reviews the significant studies published to date in the area of the pharmacogenetics of antiretroviral therapy and summarizes current trends, as well as areas where further research is needed.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15206060 DOI: 10.1086/421557
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079